Share on LinkedInShare on LinkedIn

ARTICLE · 20 AUGUST 2020

Bioethics In A Pandemic: Vaccine Distribution

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Contributor
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private...

View firm profile
Explore more from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

After months of stay-at-home orders, quarantine protocols, social distancing, and back-to-school planning...

United StatesCoronavirus (COVID-19)

After months of stay-at-home orders, quarantine protocols, social distancing, and back-to-school planning, the ever- present question on everyone's mind is, When will we get back to business as usual? For many, the answer involves discussion of a safe and effective vaccine, including when it will be available and who will be able to get it. Even though a vaccine likely won't be available until 2021 at the earliest, experts are already thinking about how to distribute it. This post is the first in a blog series that will consider the various bioethics issues and principles related to the COVID-19 pandemic.

Last month, the directors of the Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) charged a group of independent scientists and ethicists with developing guidelines to determine who should get the first doses of an FDA-approved COVID-19 vaccine.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from